Follow-The-Filings

Security · featured owners

MIRM Mirum Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 5.6%
  • $43M
  • 2 add 1 exit

MIRM (Mirum Pharmaceuticals Inc.) is held in 2 featured 13F books as of 2026 Q2. Palo Alto Investors is the largest tracked holder by portfolio weight (5.6%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 5.6% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors Add 5.6%
  2. Polen Capital Management Add 0.02%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Palo Alto Investors 2026 Q2 5.6% Add +7.3% 348,808 $41M History
Polen Capital Management 2026 Q2 0.02% Add +1.8% 20,899 $2M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 3,000 $277K History

2 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 12 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 1.01,2.03,3.02,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
DEFA14A Filing Doc
8-K/A 9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 14 rows shown

Filed Form Detail Links
4 Period Sep 11, 2026 Filing Doc
4 Period Sep 1, 2026 Filing Doc
4 Period Sep 2, 2026 Filing Doc
4 Period Aug 18, 2026 Filing Doc
4 Period Aug 11, 2026 Filing Doc
4 Period Aug 10, 2026 Filing Doc
4 Period Aug 3, 2026 Filing Doc
4 Period Jul 6, 2026 · 2 forms Filing Doc
4 Period Jul 1, 2026 Filing Doc
4 Period Jun 17, 2026 Filing Doc
4 Period Jun 15, 2026 · 8 forms Filing Doc
4 Period Jun 8, 2026 Filing Doc
4 Period Jun 5, 2026 Filing Doc
4 Period May 29, 2026 · 4 forms Filing Doc

Updated 1 day ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $186.37M $336.89M $521.31M
Net income -$163.42M -$87.94M -$23.36M
Net margin * -87.7% -26.1% -4.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $387.54M $392.79M $549.68M
Total non-current assets * $259.08M $277.97M $293.13M
Total assets $646.62M $670.75M $842.81M
Total current liabilities $87.06M $126.55M $205.8M
Total non-current liabilities * $310.89M $318.56M $322.32M
Total equity $248.67M $225.64M $314.69M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.94M $10.32M $55.83M
Cash from investing -$107.2M -$90.12M -$23.95M
Cash from financing $336.6M $17.7M $40.14M
Net change in cash $158.32M -$63.4M $75.24M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders